



Patented
Medicine Prices
Review Board

Conseil d'examen
du prix des médicaments
brevetés

**IN THE MATTER OF the Patent Act R.S.C. 1985, c. P-4
as amended**

**AND IN THE MATTER OF the medicine ONCASPAR (pegaspargase) sold in
Canada by Baxalta Canada Corporation**

PANEL ORDER

WHEREAS Board Staff's Notice of Application seeks an order requiring Baxalta Canada Corporation ("Baxalta") to provide the Patented Medicine Prices Review Board with the information referred to in section 80 of the Patent Act and sections 3 and 4 of the Patented Medicines Regulations in respect of the drug product, Oncaspar.

AND WHEREAS Baxalta has agreed to provide the information sought by Board Staff for the period commencing July 1, 2015, when Baxalta began to sell Oncaspar in Canada.

AND WHEREAS Board Staff, with the consent of Baxalta, has requested that this application be discontinued.

The Panel hereby orders that this application be discontinued.

DATED in Ottawa, this 28th day of October, 2016

Original signed by

Dr. Mitchell Levine on behalf of the Panel.